CAR Therapy Clinical Safety Endpoint Monitoring Services

Q: Q1: What safety endpoints does this service cover?

A1: We cover three critical safety domains: acute toxicity via CRS biomarker profiling, vector safety via RCL detection, and long-term genotoxicity via lentiviral integration site analysis (ISA) with insertional mutagenesis risk assessment.

Online Inquiry

Background Service Service Packages Highlights FAQs Contact

The clinical translation of CAR-T cell therapies remains constrained by critical safety liabilities, including cytokine release syndrome (CRS), replication-competent lentivirus (RCL) contamination, and insertional mutagenesis, each demanding rigorous, continuous surveillance throughout the product lifecycle. Our CAR Therapy Clinical Safety Endpoint Monitoring Services provide a comprehensive, regulatory-aligned solution that simultaneously addresses these three core safety domains. Built upon multiplex high-throughput immunoassays, validated RCL detection systems, and high-resolution integration site analysis coupled with proprietary bioinformatics, our platform delivers ultrasensitive, real-time safety data from infusion through long-term follow-up. By consolidating acute toxicity, vector safety, and genotoxicity monitoring into one seamless framework, we empower you with early warning signals, standardised regulatory dossiers, and data continuity that accelerates clinical development and strengthens product lifecycle management.

Introduction

Chimeric antigen receptor (CAR) T-cell therapy represents a transformative paradigm in oncology, reprogramming autologous or allogeneic lymphocytes to recognise and eliminate tumour-associated antigens with remarkable specificity. However, this potent biological modality carries inherent safety concerns, including cytokine release syndrome, off-tumour toxicity, and vector-related genotoxicity, that demand rigorous, life-cycle-long surveillance to ensure patient welfare and regulatory compliance.

Fig.1 Production, deployment, and efficacy monitoring of CAR T-cells. (OA Literature) Fig.1 Preparation, therapeutic application, and performance assessment of CAR-T cells.¹

Our Service

Our unified safety surveillance framework tackles the three principal risk domains in CAR-T cell therapy, cytokine release syndrome, replication-competent lentiviral contamination, and insertional oncogenic potential. Leveraging high-plex cytokine profiling, regulatory-qualified RCL screening, and high-definition integration site mapping driven by in-house bioinformatics pipelines, we generate submission-ready, longitudinal safety intelligence spanning initial infusion to extended post-treatment surveillance.

Service Packages

Multiplex High-Throughput Cytokine Release Syndrome (CRS) Biomarker Detection Service

This service provides robust, parallel quantification of key pro-inflammatory and anti-inflammatory cytokines (e.g., IL-6, IFN-γ, TNF-α) using automated multiplex platforms, enabling real-time, high-frequency monitoring of CRS onset and severity in CAR-T recipients. It supports early risk stratification, guides timely immunomodulatory interventions, and generates quantitative data streams.

Learn More →

Replication-Competent Lentivirus (RCL) Regulatory Compliance Assay (VSV-G / Wild-Type)

This assay suite delivers validated, regulatory-grade detection of replication-competent lentivirus, including VSV-G pseudotyped and wild-type recombinants, using sensitive amplification and readout systems. It ensures batch-release testing, vector lot qualification, and long-term patient monitoring meet strict safety thresholds, thereby mitigating the risk of insertional reactivation or secondary transmission.

Learn More →

Lentiviral Integration Site Analysis (ISA) & Insertion Mutagenesis Safety Evaluation

This service combines high-throughput sequencing-based integration site profiling with bioinformatic clonal tracking to map vector-genome junctions across transduced cell populations. It assesses potential oncogene proximity, epigenomic hot spots, and clonal dominance over time, providing a quantitative risk assessment for insertional mutagenesis.

Learn More →

Key Advantages

End-to-End Integrated Risk Coverage: Our service consolidates acute toxicity, vector safety, and long-term genotoxicity within a single unified framework, eliminating data fragmentation and assay standardisation discrepancies that typically arise from managing multiple CROs across different safety domains.
Ultra-Sensitive Early Warning Capability: In CRS monitoring, high-throughput multiplexing enables simultaneous capture of early cytokine elevation signals from a single micro-sample, offering broader dynamic ranges and lower detection limits than conventional ELISA to facilitate pre-emptive clinical intervention hours before symptom escalation.
High-Resolution Clonal Hazard Surveillance: For integration site analysis, deep sequencing coupled with proprietary bioinformatics allows robust tracking of low-abundance integrants, providing pre-symptomatic alerts for potential malignant transformation linked to insertional mutagenesis.
Regulatory-Grade Standardised Data Output: Our platform delivers customised safety reports featuring trend visualisation and tiered risk classification, which not only expedite clinical safety review cycles but also generate a consistent, comparable safety baseline across autologous, allogeneic, and dual-targeted CAR-T products.

FAQ

Q1: What safety endpoints does this service cover?

A1: We cover three critical safety domains: acute toxicity via CRS biomarker profiling, vector safety via RCL detection, and long-term genotoxicity via lentiviral integration site analysis (ISA) with insertional mutagenesis risk assessment.

Q2: At what time points should samples be collected for CRS monitoring?

A2: We recommend a pre-infusion baseline, followed by daily sampling during the peak risk window, with extended monitoring through day 28 or until clinical resolution, depending on your trial protocol and cytokine dynamics.

Why Choose Us?

We offer the only integrated platform that simultaneously monitors CRS dynamics, RCL regulatory compliance, and insertional mutagenesis risk, all under one validated framework. Our ultrasensitive assays and regulatory-grade bioinformatics deliver early warning signals, standardised safety dossiers, and seamless IND-to-post-marketing continuity, empowering decisive clinical action with uncompromised quality.

How to contact us?

Our scientific and regulatory experts are ready to tailor a safety monitoring strategy for your CAR-T program. Reach out to discuss assay design, timeline optimization, or submission planning. We respond with preliminary feasibility and a customized proposal aligned with your development milestones.

Reference

Chen, Qiuqiang et al. "Efficacy, Safety, and Challenges of CAR T-Cells in the Treatment of Solid Tumors." Cancers vol. 14,23 5983. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3390/cancers14235983.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.